Pharmocann Global Past Earnings Performance
Past criteria checks 0/6
Pharmocann Global has been growing earnings at an average annual rate of 1.5%, while the Pharmaceuticals industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 0.1% per year.
Key information
1.5%
Earnings growth rate
23.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 0.1% |
| Return on equity | -1,279.1% |
| Net Margin | -67.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence
Mar 30
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?
Feb 04Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 31
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come
Nov 26Revenue & Expenses BreakdownBeta
How Pharmocann Global makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14 | -10 | 8 | 0 |
| 30 Sep 23 | 14 | -19 | 9 | 1 |
| 30 Jun 23 | 15 | -25 | 10 | 1 |
| 31 Mar 23 | 19 | -28 | 11 | 1 |
| 31 Dec 22 | 23 | -25 | 13 | 1 |
| 30 Sep 22 | 24 | -23 | 12 | 1 |
| 30 Jun 22 | 25 | -20 | 13 | 1 |
| 31 Mar 22 | 28 | -16 | 15 | 1 |
| 31 Dec 21 | 29 | -19 | 15 | 1 |
| 30 Sep 21 | 31 | -14 | 15 | 1 |
| 30 Jun 21 | 32 | -7 | 15 | 1 |
| 31 Mar 21 | 31 | 2 | 13 | 1 |
| 31 Dec 20 | 28 | 4 | 13 | 1 |
| 30 Sep 20 | 26 | 6 | 11 | 1 |
| 30 Jun 20 | 26 | 5 | 10 | 1 |
| 31 Mar 20 | 21 | -25 | 9 | 1 |
| 31 Dec 19 | 21 | -46 | 6 | 1 |
| 30 Sep 19 | 18 | -46 | 6 | 0 |
| 30 Jun 19 | 17 | -46 | 4 | 0 |
| 31 Mar 19 | 16 | -20 | 4 | 0 |
| 31 Dec 18 | 15 | 6 | 3 | 0 |
| 31 Dec 17 | 12 | 2 | 3 | 0 |
| 31 Dec 16 | 9 | 1 | 2 | 0 |
Quality Earnings: PMCN-M is currently unprofitable.
Growing Profit Margin: PMCN-M is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 1.5% per year.
Accelerating Growth: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.7%).
Return on Equity
High ROE: PMCN-M has a negative Return on Equity (-1279.11%), as it is currently unprofitable.